NASDAQ$IART

Integra LifeSciences Holdings Corporation · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Integra LifeSciences' Q3 2024 financial performance reflected a decrease in revenue and earnings per share compared to the prior year, while shipping holds were releasing as expected and Integra Skin production was on pace.

Integra LifeSciences reported a slight decrease in third-quarter revenue and a significant drop in GAAP and adjusted earnings per share compared to the previous year. The company is progressing with its compliance master plan and announced Mojdeh Poul as the next president and CEO.

  • Third quarter revenues decreased 0.4% on a reported basis and 8.6% on an organic basis.
  • GAAP earnings per diluted share were $(0.14), compared to $0.24 in the prior year; adjusted earnings per diluted share was $0.41, compared to $0.76 in the prior year.
  • Shipping holds communicated during the second quarter earnings call are releasing in line with expectations.
  • Integra Skin production is on pace to meet historical revenue run rates for the fourth quarter.

Headline financials

Total Revenue

$381M

Previous: $382M-0.4%
EPS

-$0.14

Previous: $0.76-118.4%
Capital Expenditures

-$74.8M

Previous: -$42.3M-76.7%
Free Cash Flow

-$85.5M

Previous: -$22.8M-274.5%
Net Income

-$10.7M

Previous: $19.5M-154.9%
Operating Income

-$8.15M

Previous: $26.6M-130.6%
Gross Profit

$200M

Previous: $218M-8.3%
Cash & Equivalents

$215M

Previous: $274M-21.4%
Total Assets

$4.07B

Previous: $3.74B+8.7%
R&D Expense

$29.1M

Previous: $27.7M+5.1%
Stock-Based Comp

$4.38M

Previous: $5.46M-19.7%

Revenue & EPS history

Integra LifeSciences · Revenue · Quarterly

$381M

Q3 2024-0.4%vs Q3 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Integra LifeSciences · $360M total across 4 segments · Q1 2021

  • Neurosurgery
    $189M+2.3%
  • Wound Reconstruction and Care
    $88.7M+22.7%
  • Instruments
    $52M+11.8%
  • Private Label
    $30.1M+3.4%

Forward guidance

For the fourth quarter 2024, the Company expects reported revenues in the range of $441 million to $451 million, representing reported growth of 11.1% to 13.6% and organic growth of 2.0% to 4.5%. The Company expects adjusted EPS in a range of $0.81 to $0.89. For the full year 2024, the Company is updating its revenue and adjusted EPS ranges of $1.609 billion to $1.619 billion and $2.41 to $2.49, respectively. The revenue range represents reported growth of 4.4% to 5.0% and organic growth of -1.7% to -1.0%.

Tailwinds

  • Integration of Acclarent.
  • Stepped up revenue from progress clearing the third-quarter shipping holds.
  • Improved production for Integra Skin.

Headwinds

  • Additional quality holds.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-0.2%

Avg return

Earnings day

-1.4%

Avg return

5 days after

-1.8%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+29.2%

Q3 2024

Best reaction

-23.5%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+24.4%+31.0%+65.1%
Q4 2025-2.1%-8.9%-20.6%
Q3 2025-23.5%-26.8%-15.0%
Q1 2025-20.9%-27.3%-22.3%
Q4 2024+12.1%+5.3%-0.2%
Q3 2024+29.2%+28.5%+25.1%
Q2 2024-20.4%-23.5%-35.3%
Q1 2024-13.2%-10.0%+9.9%
Q4 2023-16.6%-18.8%-19.9%
Q3 2023-4.5%-5.8%+6.3%
Q2 2023-3.1%-1.1%-9.5%
Q1 2023-6.2%-5.5%-34.7%
Q4 2022+0.2%+0.8%-3.1%
Q3 2022+11.1%+12.7%+21.1%
Q2 2022-1.5%-0.5%-14.8%
Q1 2022+2.9%-0.2%+2.5%
Q4 2021+0.9%+2.6%-2.8%
Q3 2021+7.1%+7.5%-5.3%
Q2 2021-0.2%-0.3%+2.6%
Q1 2021-2.0%-3.4%-9.9%
Q4 2020-4.1%-2.8%-6.2%
Q3 2020-7.0%-4.5%+19.5%
Q2 2020+6.4%+6.6%-5.6%
Q1 2020+1.5%-2.8%+7.9%
Q4 2019+2.9%-0.3%-35.7%
Q3 2019-7.7%-5.1%-2.0%
Q2 2019+12.0%+14.5%+8.0%
Q1 2019-3.1%-2.3%-7.7%
Q4 2018+5.7%+6.1%+6.5%
Q3 2018-12.6%-13.5%-13.9%
Q2 2018-2.3%-2.3%-5.5%
Q1 2018+9.8%+12.7%+16.7%
Q4 2017-4.1%-4.1%+0.7%
Q3 2017-9.1%-8.2%-4.9%
Q2 2017-9.9%-10.7%-10.9%
Q1 2017+4.6%+5.1%+12.1%
Q4 2016-2.1%-1.2%-1.2%
Q3 2016+1.6%-3.4%+3.8%
Q2 2016+6.8%+6.4%+9.0%
Q1 2016+6.7%
Q4 2015+3.8%
Q3 2015+2.8%
Q2 2015-0.1%
Q1 2015+7.5%
Q4 2014+2.3%
Q3 2014-7.5%
Q2 2014+1.0%
Q1 2014-1.6%
Q4 2013-3.9%
Q3 2013+4.4%
Q2 2013-2.2%
Q1 2013+0.2%
Q4 2012-4.8%
Q3 2012-0.3%
Q2 2012+4.1%
Q1 2012+9.4%
Q4 2011+1.2%
Q3 2011-21.8%
Q2 2011-5.3%
Q1 2010+2.1%
Q1 2011+0.8%
Q4 2008-0.7%
Q4 2010-0.7%
Q3 2010+2.2%
Q3 2009+2.2%
Q2 2009+6.2%
Q2 2010+6.2%
Q4 2009+6.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro